Press Release

August 28, 2023

Abata Therapeutics to Present and Participate in Upcoming Investor and Industry Events

August 24, 2023

Abata Therapeutics Announces Second Development Candidate, ABA-201, a Novel Treg Cell Therapy for the Treatment of Type 1 Diabetes

Abata Therapeutics to Present at Upcoming Investor and Industry Events in June

Abata Therapeutics Announces the Appointment of Leonard Dragone, M.D., Ph.D., as Chief Medical Officer

December 14, 2022

Abata Therapeutics Announces First Development Candidate, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis

December 7, 2022

Abata Therapeutics Appoints Ellen Cahir-McFarland, Ph.D., as Chief Scientific Officer

November 9, 2022

Abata Therapeutics to Participate in Guggenheim’s 4th Annual Immunology and Neurology Day

August 31, 2022

Abata Therapeutics to Present at Upcoming September Investor Conferences

Abata Therapeutics to Participate in the Guggenheim I&I Spotlight Series – Treg-Based Therapies